

JosÃ© Eduardo Tanus-Santos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7155310/publications.pdf>

Version: 2024-02-01

330
papers

12,838
citations

30070

54
h-index

39675

94
g-index

331
all docs

331
docs citations

331
times ranked

10996
citing authors

#	ARTICLE	IF	CITATIONS
1	The use of probiotics can reduce the severity of experimental periodontitis in rats with metabolic syndrome: An immunoenzymatic and microtomographic study. <i>Journal of Periodontology</i> , 2022, 93, .	3.4	10
2	Gene-gene interactions in the protein kinase C/endothelial nitric oxide synthase axis impact the hypotensive effects of propofol. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 130, 277-287.	2.5	2
3	Matrix Metalloproteinases on Severe COVID-19 Lung Disease Pathogenesis: Cooperative Actions of MMP-8/MMP-2 Axis on Immune Response through HLA-G Shedding and Oxidative Stress. <i>Biomolecules</i> , 2022, 12, 604.	4.0	28
4	Nitrate and nitrite-based therapy to attenuate cardiovascular remodelling in arterial hypertension. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 128, 9-17.	2.5	8
5	Assessment of nitric oxide metabolites concentrations in plasma, saliva, and breast milk and their relationship in lactating women. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 1293-1302.	3.1	3
6	Oral nitrite treatment increases S-nitrosylation of vascular protein kinase C and attenuates the responses to angiotensin II. <i>Redox Biology</i> , 2021, 38, 101769.	9.0	14
7	Circulating Total Cell-Free DNA Levels Are Increased in Hypertensive Disorders of Pregnancy and Associated with Prohypertensive Factors and Adverse Clinical Outcomes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 564.	4.1	11
8	A new mixed model of periodontitis-induced preeclampsia: A pilot study. <i>Journal of Periodontal Research</i> , 2021, 56, 726-734.	2.7	4
9	Matrix Metalloproteinases and Arterial Hypertension: Role of Oxidative Stress and Nitric Oxide in Vascular Functional and Structural Alterations. <i>Biomolecules</i> , 2021, 11, 585.	4.0	32
10	Association between endothelial nitric oxide synthase and the renin-angiotensin-aldosterone system polymorphisms, blood pressure and training status in normotensive/pre-hypertension and hypertensive older adults: a pilot study. <i>Clinical and Experimental Hypertension</i> , 2021, 43, 661-670.	1.3	4
11	<i>NAMPT</i> single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia. <i>Pharmacogenomics</i> , 2021, 22, 451-464.	1.3	7
12	Omeprazole induces vascular remodeling by mechanisms involving xanthine oxidoreductase and matrix metalloproteinase activation. <i>Biochemical Pharmacology</i> , 2021, 190, 114633.	4.4	5
13	Antiseptic mouthwash inhibits antihypertensive and vascular protective effects of L-arginine. <i>European Journal of Pharmacology</i> , 2021, 907, 174314.	3.5	4
14	Nitrite and tempol combination promotes synergic effects and alleviates right ventricular wall stress during acute pulmonary thromboembolism. <i>Nitric Oxide - Biology and Chemistry</i> , 2021, 115, 23-29.	2.7	2
15	Antioxidant tempol modulates the increases in tissue nitric oxide metabolites concentrations after oral nitrite administration. <i>Chemico-Biological Interactions</i> , 2021, 349, 109658.	4.0	4
16	Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 869-877.	1.9	6
17	Treatment with nitrite prevents reactive oxygen species generation in the corpora cavernosa and restores intracavernosal pressure in hypertensive rats. <i>Nitric Oxide - Biology and Chemistry</i> , 2020, 94, 19-26.	2.7	5
18	Association of 11 β -hydroxysteroid dehydrogenase type1 (HSD11b1) gene polymorphisms with outcome of antidepressant therapy and suicide attempts. <i>Behavioural Brain Research</i> , 2020, 381, 112343.	2.2	5

#	ARTICLE	IF	CITATIONS
19	Verapamil decreases calpain-1 and matrix metalloproteinase-2 activities and improves hypertension-induced hypertrophic cardiac remodeling in rats. <i>Life Sciences</i> , 2020, 244, 117153.	4.3	10
20	A comprehensive time course study of tissue nitric oxide metabolites concentrations after oral nitrite administration. <i>Free Radical Biology and Medicine</i> , 2020, 152, 43-51.	2.9	8
21	Consistent gastric pH-dependent effects of suppressors of gastric acid secretion on the antihypertensive responses to oral nitrite. <i>Biochemical Pharmacology</i> , 2020, 177, 113940.	4.4	10
22	Plasma levels of matrix metalloproteinase-9 are elevated in individuals with hypertensive crisis. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 132.	1.7	17
23	Letter by de Paula et al Regarding Article, "Improvement in Outcomes After Cardiac Arrest and Resuscitation by Inhibition of S-Nitrosoglutathione Reductase"; <i>Circulation</i> , 2019, 140, e190-e191.	1.6	0
24	DDAH1 and DDAH2 polymorphisms associate with asymmetrical dimethylarginine plasma levels in erectile dysfunction patients but not in healthy controls. <i>Nitric Oxide - Biology and Chemistry</i> , 2019, 92, 11-17.	2.7	5
25	Antioxidant and antihypertensive responses to oral nitrite involves activation of the Nrf2 pathway. <i>Free Radical Biology and Medicine</i> , 2019, 141, 261-268.	2.9	29
26	NAMPT levels are inversely related to nitric oxide formation and positively related to soluble fms-like tyrosine kinase-1 levels in preeclampsia. <i>Pregnancy Hypertension</i> , 2019, 18, 137-140.	1.4	7
27	Mechanisms impairing blood pressure responses to nitrite and nitrate. <i>Nitric Oxide - Biology and Chemistry</i> , 2019, 85, 35-43.	2.7	32
28	Nitrite-stimulated Gastric Formation of S-nitrosothiols As An Antihypertensive Therapeutic Strategy. <i>Current Drug Targets</i> , 2019, 20, 431-443.	2.1	16
29	Sodium nitrite improves hypertension-induced myocardial dysfunction by mechanisms involving cardiac S-nitrosylation. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 134, 40-50.	1.9	15
30	Activation of the TRKB receptor mediates the panicolytic-like effect of the NOS inhibitor aminoguanidine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 93, 232-239.	4.8	10
31	Increased Proton Pump Inhibitors-Induced Mortality Risk in Hemodialysis Patients. <i>Kidney International Reports</i> , 2019, 4, 505.	0.8	0
32	Proton pump inhibitors: New mechanisms of action. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 125, 87-88.	2.5	4
33	Circulating HO-1 levels are not associated with plasma sFLT-1 and GTN polymorphism in preeclampsia. <i>Hypertension in Pregnancy</i> , 2019, 38, 73-77.	1.1	3
34	Nitric oxide in the dorsal periaqueductal gray mediates the panic-like escape response evoked by exposure to hypoxia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 92, 321-327.	4.8	9
35	Gastroesophageal Reflux Treatment With Proton Pump Inhibitors in Patients With Hypertension. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 157-158.	2.2	3
36	<p><p>Pharmacogenomics And Hypertension: Current Insights</p><p><p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2019, Volume 12, 341-359.	0.7	25

#	ARTICLE	IF	CITATIONS
37	Nitrite treatment downregulates vascular MMP-2 activity and inhibits vascular remodeling in hypertension independently of its antihypertensive effects. <i>Free Radical Biology and Medicine</i> , 2019, 130, 234-243.	2.9	24
38	Mechanisms involved in proton pump inhibitors-induced increases in ischemic events. <i>Atherosclerosis</i> , 2019, 280, 197-198.	0.8	0
39	Comment on "Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomised controlled VaSera trial" by Faconti et al. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1035-1036.	2.4	2
40	Endothelial nitric oxide synthase polymorphisms affect the changes in blood pressure and nitric oxide bioavailability induced by propofol. <i>Nitric Oxide - Biology and Chemistry</i> , 2018, 75, 77-84.	2.7	14
41	Quercetin decreases the activity of matrix metalloproteinase-2 and ameliorates vascular remodeling in renovascular hypertension. <i>Atherosclerosis</i> , 2018, 270, 146-153.	0.8	49
42	Direct renin inhibition is not enough to prevent reactive oxygen species generation and vascular dysfunction in renovascular hypertension. <i>European Journal of Pharmacology</i> , 2018, 821, 97-104.	3.5	10
43	Preeclamptic plasma stimulates the expression of miRNAs, leading to a decrease in endothelin-1 production in endothelial cells. <i>Pregnancy Hypertension</i> , 2018, 12, 75-81.	1.4	19
44	Nitrite exerts antioxidant effects, inhibits the mTOR pathway and reverses hypertension-induced cardiac hypertrophy. <i>Free Radical Biology and Medicine</i> , 2018, 120, 25-32.	2.9	24
45	Contrasting effects of low versus high ascorbate doses on blood pressure responses to oral nitrite in L-NAME-induced hypertension. <i>Nitric Oxide - Biology and Chemistry</i> , 2018, 74, 65-73.	2.7	10
46	Dysregulated mitogen-activated protein kinase and matrix metalloproteinase in ethanol-induced cavernosal dysfunction. <i>Canadian Journal of Physiology and Pharmacology</i> , 2018, 96, 266-274.	1.4	3
47	Angiotensin converting enzyme inhibitors enhance the hypotensive effects of propofol by increasing nitric oxide production. <i>Free Radical Biology and Medicine</i> , 2018, 115, 10-17.	2.9	13
48	Association of endothelial nitric oxide synthase (eNOS) gene polymorphisms and physical fitness levels with plasma nitrite concentrations and arterial blood pressure values in older adults. <i>PLoS ONE</i> , 2018, 13, e0206254.	2.5	6
49	Pharmacogenetic relevance of endothelial nitric oxide synthase polymorphisms and gene interactions. <i>Pharmacogenomics</i> , 2018, 19, 1423-1435.	1.3	12
50	Preliminary study about the relationship between estimated training status and RAS polymorphisms on blood pressure and ACE activity in the elderly. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2018, 19, 147032031878262.	1.7	1
51	Matrix metalloproteinase-2-induced epidermal growth factor receptor transactivation impairs redox balance in vascular smooth muscle cells and facilitates vascular contraction. <i>Redox Biology</i> , 2018, 18, 181-190.	9.0	27
52	Serum or Plasma Matrix Metalloproteinase (MMP)-9 Levels and Cardiovascular Diseases. <i>Journal of Cardiovascular Translational Research</i> , 2018, 11, 524-525.	2.4	6
53	Nitrate decreases xanthine oxidoreductase-mediated nitrite reductase activity and attenuates vascular and blood pressure responses to nitrite. <i>Redox Biology</i> , 2017, 12, 291-299.	9.0	25
54	Myeloperoxidase in Hypertensive Disorders of Pregnancy and Its Relation With Nitric Oxide. <i>Hypertension</i> , 2017, 69, 1173-1180.	2.7	21

#	ARTICLE	IF	CITATIONS
55	The potential of stimulating nitric oxide formation in the treatment of hypertension. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 543-556.	3.4	32
56	Matrix Metalloproteinase-2 Activity is Associated with Divergent Regulation of Calponin-1 in Conductance and Resistance Arteries in Hypertension-Induced Early Vascular Dysfunction and Remodelling. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 246-256.	2.5	11
57	Relationship between asymmetric dimethylarginine, nitrite and genetic polymorphisms: Impact on erectile dysfunction therapy. <i>Nitric Oxide - Biology and Chemistry</i> , 2017, 71, 44-51.	2.7	7
58	Gene-Gene Interactions Among PRKCA, NOS3 and BDKRB2 Polymorphisms Affect the Antihypertensive Effects of Enalapril. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 120, 284-291.	2.5	26
59	Impaired xanthine oxidoreductase (XOR)-mediated nitrite reductase activity possibly involved in the lack of antihypertensive effects of XOR inhibitors. <i>Hypertension Research</i> , 2017, 40, 301-301.	2.7	3
60	Clinical and pharmacogenetic impact of endothelial nitric oxide synthase polymorphisms on cardiovascular diseases. <i>Nitric Oxide - Biology and Chemistry</i> , 2017, 63, 39-51.	2.7	52
61	Inducible Nitric Oxide Synthase Polymorphisms and Nitric Oxide Levels in Individuals with Chronic Periodontitis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1128.	4.1	13
62	Effect of Multicomponent Training on Blood Pressure, Nitric Oxide, Redox Status, and Physical Fitness in Older Adult Women: Influence of Endothelial Nitric Oxide Synthase (NOS3) Haplotypes. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-12.	4.0	13
63	Training Status as a Marker of the Relationship between Nitric Oxide, Oxidative Stress, and Blood Pressure in Older Adult Women. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-9.	4.0	6
64	C-Type Natriuretic Peptide Induces Anti-contractile Effect Dependent on Nitric Oxide, Oxidative Stress, and NPR-B Activation in Sepsis. <i>Frontiers in Physiology</i> , 2016, 7, 226.	2.8	8
65	Antihypertensive therapy in pre-eclampsia: effects of plasma from nonresponsive patients on endothelial gene expression. <i>Pharmacogenomics</i> , 2016, 17, 1121-1127.	1.3	10
66	NADPH Oxidase Plays a Role on Ethanol-Induced Hypertension and Reactive Oxygen Species Generation in the Vasculature. <i>Alcohol and Alcoholism</i> , 2016, 51, 522-534.	1.6	29
67	Endothelial nitric oxide synthase tagSNPs influence the effects of enalapril in essential hypertension. <i>Nitric Oxide - Biology and Chemistry</i> , 2016, 55-56, 62-69.	2.7	19
68	Role of adiponectin on antioxidant profile: evaluation during healthy and hypertensive disorders of pregnancy. <i>Blood Pressure</i> , 2016, 25, 241-243.	1.5	9
69	Tempol improves xanthine oxidoreductase-mediated vascular responses to nitrite in experimental renovascular hypertension. <i>Redox Biology</i> , 2016, 8, 398-406.	9.0	20
70	Plasma matrix metalloproteinase-9 levels, MMP-9 gene haplotypes, and cardiovascular risk in obese subjects. <i>Molecular Biology Reports</i> , 2016, 43, 463-471.	2.3	17
71	Mechanisms involved in cardiovascular protection associated with a vegetarian diet. <i>Clinica Chimica Acta</i> , 2016, 462, 40.	1.1	0
72	Omeprazole impairs vascular redox biology and causes xanthine oxidoreductase-mediated endothelial dysfunction. <i>Redox Biology</i> , 2016, 9, 134-143.	9.0	40

#	ARTICLE	IF	CITATIONS
73	Lack of association between genetic polymorphism of FTO, AKT1 and AKTIP in childhood overweight and obesity. <i>Jornal De Pediatria</i> , 2016, 92, 521-527.	2.0	15
74	Plasma from pre-eclamptic patients induces the expression of the anti-angiogenic miR-195 in endothelial cells. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 1198-1200.	3.6	30
75	Matrix metalloproteinase (MMP)-2 decreases calponin-1 levels and contributes to arterial remodeling in early hypertension. <i>Biochemical Pharmacology</i> , 2016, 118, 50-58.	4.4	24
76	Oral nitrite circumvents antiseptic mouthwash-induced disruption of enterosalivary circuit of nitrate and promotes nitrosation and blood pressure lowering effect. <i>Free Radical Biology and Medicine</i> , 2016, 101, 226-235.	2.9	33
77	Longitudinal assessment of maternal-fetal Doppler parameters and maternal plasma level of matrix metalloproteinases 2 and 9. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2016, 29, 3967-3970.	1.5	2
78	Sodium nitrite attenuates MMP-9 production by endothelial cells and may explain similar effects of atorvastatin. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2016, 389, 223-231.	3.0	12
79	Assessment of nitrite oxide and maternal-fetal Doppler parameters during pregnancy. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2016, 29, 1-4.	1.5	0
80	Evaluation of the in vivo thrombolytic activity of a metalloprotease from Bothrops atrox venom using a model of venous thrombosis. <i>Toxicon</i> , 2016, 109, 18-25.	1.6	16
81	Association of Mineralocorticoid Receptor Polymorphism I180V With Left Ventricular Hypertrophy in Resistant Hypertension. <i>American Journal of Hypertension</i> , 2016, 29, 245-250.	2.0	11
82	Endothelial nitric oxide synthase: From biochemistry and gene structure to clinical implications of NOS3 polymorphisms. <i>Gene</i> , 2016, 575, 584-599.	2.2	95
83	Increased activity of MMP-2 in hypertensive obese children is associated with hypoadiponectinemia. <i>Obesity</i> , 2015, 23, 177-182.	3.0	15
84	The Nuclear Factor κ B Inhibitor Pyrrolidine Dithiocarbamate Prevents Cardiac Remodelling and Matrix Metalloproteinase-2 Up-Regulation in Renovascular Hypertension. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 234-241.	2.5	28
85	Vascular Damage in Resistant Hypertension: TNF-Alpha Inhibition Effects on Endothelial Cells. <i>BioMed Research International</i> , 2015, 2015, 1-8.	1.9	30
86	Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 949-957.	1.9	27
87	Effects of NAMPT polymorphisms and haplotypes on circulating visfatin/NAMPT levels in hypertensive disorders of pregnancy. <i>Hypertension Research</i> , 2015, 38, 361-366.	2.7	22
88	Relationship between Arginase 1 and Arginase 2 levels and genetic polymorphisms with erectile dysfunction. <i>Nitric Oxide - Biology and Chemistry</i> , 2015, 51, 36-42.	2.7	25
89	Atorvastatin and sildenafil decrease vascular TGF- β 2 levels and MMP-2 activity and ameliorate arterial remodeling in a model of renovascular hypertension. <i>Redox Biology</i> , 2015, 6, 386-395.	9.0	30
90	Adiponectin Δ 1377C/G and +276G/T Polymorphisms affect Adiponectin Levels but do not Modify Responsiveness to Therapy in Resistant Hypertension. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 65-72.	2.5	10

#	ARTICLE	IF	CITATIONS
91	Antihypertensive therapy in preeclampsia is not modulated by VEGF polymorphisms. Archives of Gynecology and Obstetrics, 2015, 291, 799-803.	1.7	8
92	Gastric S-nitrosothiol formation drives the antihypertensive effects of oral sodium nitrite and nitrate in a rat model of renovascular hypertension. Free Radical Biology and Medicine, 2015, 87, 252-262.	2.9	71
93	Positive correlations between circulating adiponectin and MMP2 in preeclampsia pregnant. Pregnancy Hypertension, 2015, 5, 205-208.	1.4	39
94	Genetic Effects of eNOS Polymorphisms on Biomarkers Related to Cardiovascular Status in a Population Coexposed to Methylmercury and Lead. Archives of Environmental Contamination and Toxicology, 2015, 69, 173-180.	4.1	10
95	Combining drugs to optimize the therapy of hypertension: experimental evidence derived from animal models. Hypertension Research, 2015, 38, 457-458.	2.7	1
96	Consistent antioxidant and antihypertensive effects of oral sodium nitrite in DOCA-salt hypertension. Redox Biology, 2015, 5, 340-346.	9.0	50
97	Correlations among antiangiogenic factors and trace elements in hypertensive disorders of pregnancy. Journal of Trace Elements in Medicine and Biology, 2015, 29, 130-135.	3.0	19
98	Targeting Matrix Metalloproteinases in Disease Conditions. Acupuncture in Medicine, 2014, 32, 373-375.	1.0	4
99	Letter by Pinheiro et al Regarding Article, "Unexpected Effect of Proton Pump Inhibitors: Elevation of the Cardiovascular Risk Factor Asymmetric Dimethylarginine". Circulation, 2014, 129, e427.	1.6	7
100	Hemolysis during cardiac surgery is associated with increased intravascular nitric oxide consumption and perioperative kidney and intestinal tissue damage. Frontiers in Physiology, 2014, 5, 340.	2.8	94
101	<i>MDR-1</i> ^{C3435T} polymorphism may affect blood pressure in resistant hypertensive patients independently of its effects on aldosterone release. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2014, 15, 170-176.	1.7	6
102	Effects of Angiotensin-Converting Enzyme Inhibition on Leptin and Adiponectin Levels in Essential Hypertension. Basic and Clinical Pharmacology and Toxicology, 2014, 114, 472-475.	2.5	24
103	Antioxidant effect of doxycycline decreases MMP activity and blood pressure in SHR. Molecular and Cellular Biochemistry, 2014, 386, 99-105.	3.1	37
104	Effect of Genetic Polymorphisms of Vascular Endothelial Growth Factor on Left Ventricular Hypertrophy in Patients With Systemic Hypertension. American Journal of Cardiology, 2014, 113, 491-496.	1.6	14
105	Captopril and Lisinopril Only Inhibit Matrix Metalloproteinase-2 (MMP-2) Activity at Millimolar Concentrations. Basic and Clinical Pharmacology and Toxicology, 2014, 114, 233-239.	2.5	13
106	nNOS polymorphisms are associated with responsiveness to sildenafil in clinical and postoperative erectile dysfunction. Pharmacogenomics, 2014, 15, 775-784.	1.3	11
107	Pharmacogenetics of erectile dysfunction: navigating into uncharted waters. Pharmacogenomics, 2014, 15, 1519-1538.	1.3	30
108	Vascular xanthine oxidoreductase contributes to the antihypertensive effects of sodium nitrite in l-NAME hypertension. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 591-598.	3.0	30

#	ARTICLE	IF	CITATIONS
109	Influence of training status and eNOS haplotypes on plasma nitrite concentrations in normotensive older adults: a hypothesis-generating study. <i>Aging Clinical and Experimental Research</i> , 2014, 26, 591-598.	2.9	10
110	Î²1-Adrenergic blockers exert antioxidant effects, reduce matrix metalloproteinase activity, and improve renovascular hypertension-induced cardiac hypertrophy. <i>Free Radical Biology and Medicine</i> , 2014, 73, 308-317.	2.9	37
111	The antihypertensive effects of sodium nitrite are not associated with circulating angiotensin converting enzyme inhibition. <i>Nitric Oxide - Biology and Chemistry</i> , 2014, 40, 52-59.	2.7	22
112	Inducible Nitric Oxide Synthase as a Possible Target in Hypertension. <i>Current Drug Targets</i> , 2014, 15, 164-174.	2.1	64
113	Low nitric oxide bioavailability is associated with better responses to sildenafil in patients with erectile dysfunction. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013, 386, 805-811.	3.0	17
114	Effect of metabolic syndrome risk factors and MMP-2 genetic variations on circulating MMP-2 levels in childhood obesity. <i>Molecular Biology Reports</i> , 2013, 40, 2697-2704.	2.3	25
115	Relationship between adiponectin and nitrite in healthy and preeclampsia pregnancies. <i>Clinica Chimica Acta</i> , 2013, 423, 112-115.	1.1	29
116	Nitric oxide attenuates matrix metalloproteinase-9 production by endothelial cells independent of cGMP- or NF κ B-mediated mechanisms. <i>Molecular and Cellular Biochemistry</i> , 2013, 378, 127-135.	3.1	6
117	The relationship between training status, blood pressure and uric acid in adults and elderly. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 44.	1.7	15
118	Doxycycline Prevents Acute Pulmonary Embolism-Induced Mortality and Right Ventricular Deformation in Rats. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 259-267.	2.6	19
119	Hydrogen peroxide modulates phenylephrine-induced contractile response in renal hypertensive rat aorta. <i>European Journal of Pharmacology</i> , 2013, 721, 193-200.	3.5	29
120	Tempol inhibits TGF-Î² and MMPs upregulation and prevents cardiac hypertensive changes. <i>International Journal of Cardiology</i> , 2013, 165, 165-173.	1.7	45
121	The antioxidant tempol decreases acute pulmonary thromboembolism-induced hemolysis and nitric oxide consumption. <i>Thrombosis Research</i> , 2013, 132, 578-583.	1.7	9
122	TEMPOL enhances the antihypertensive effects of sodium nitrite by mechanisms facilitating nitrite-derived gastric nitric oxide formation. <i>Free Radical Biology and Medicine</i> , 2013, 65, 446-455.	2.9	39
123	Temporal changes in cardiac matrix metalloproteinase activity, oxidative stress, and TGF-Î² in renovascular hypertension-induced cardiac hypertrophy. <i>Experimental and Molecular Pathology</i> , 2013, 94, 1-9.	2.1	51
124	Increased Circulating MMP-2 Levels in Infertile Patients With Moderate and Severe Pelvic Endometriosis. <i>Reproductive Sciences</i> , 2013, 20, 557-562.	2.5	33
125	Acute cardiac and hemodynamic effects of sildenafil on resistant hypertension. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 2027-2036.	1.9	12
126	eNOS polymorphism associated with metabolic syndrome in children and adolescents. <i>Molecular and Cellular Biochemistry</i> , 2013, 372, 155-160.	3.1	22

#	ARTICLE	IF	CITATIONS
127	Inducible nitric oxide synthase haplotype associated with hypertension and responsiveness to antihypertensive drug therapy. <i>Gene</i> , 2013, 515, 391-395.	2.2	31
128	Nebivolol attenuates prooxidant and profibrotic mechanisms involving TGF- β 2 and MMPs, and decreases vascular remodeling in renovascular hypertension. <i>Free Radical Biology and Medicine</i> , 2013, 65, 47-56.	2.9	61
129	Contrasting effects of aliskiren versus losartan on hypertensive vascular remodeling. <i>International Journal of Cardiology</i> , 2013, 167, 1199-1205.	1.7	32
130	Atorvastatin and sildenafil lower blood pressure and improve endothelial dysfunction, but only atorvastatin increases vascular stores of nitric oxide in hypertension. <i>Redox Biology</i> , 2013, 1, 578-585.	9.0	34
131	Effects of endothelial nitric oxide synthase tagSNPs haplotypes on nitrite levels in black subjects. <i>Nitric Oxide - Biology and Chemistry</i> , 2013, 28, 33-38.	2.7	20
132	Recombinant Human Matrix Metalloproteinase-2 Impairs Cardiovascular β -Adrenergic Responses. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013, 112, 103-109.	2.5	6
133	Salivary MMPs, TIMPs, and MPO levels in periodontal disease patients and controls. <i>Clinica Chimica Acta</i> , 2013, 421, 140-146.	1.1	46
134	Matrix metalloproteinase (MMP)-2 gene polymorphisms affect circulating MMP-2 levels in patients with migraine with aura. <i>Gene</i> , 2013, 512, 35-40.	2.2	35
135	Matrix Metalloproteinases: A Target in In-Stent Restenosis?. <i>Cardiology</i> , 2013, 124, 49-50.	1.4	2
136	Antioxidant effects of phosphodiesterase-5 inhibitors. <i>Cardiovascular Research</i> , 2013, 100, 170-170.	3.8	2
137	Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations. <i>Current Drug Targets</i> , 2013, 14, 335-343.	2.1	3
138	Maternal Flow-Mediated Dilation and Nitrite Concentration During Third Trimester of Pregnancy and Postpartum Period. <i>Hypertension in Pregnancy</i> , 2013, 32, 225-234.	1.1	7
139	Antihypertensive effects of inducible nitric oxide synthase inhibition in experimental pre-eclampsia. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 1300-1307.	3.6	31
140	Matrix metalloproteinase inhibition attenuates right ventricular dysfunction and improves responses to dobutamine during acute pulmonary thromboembolism. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 1588-1597.	3.6	13
141	Targeting RV failure and cardiomyocyte injury in acute pulmonary thromboembolism. <i>Nature Reviews Cardiology</i> , 2013, 10, 559-559.	13.7	1
142	Matrix Metalloproteinases as Drug Targets in Preeclampsia. <i>Current Drug Targets</i> , 2013, 14, 325-334.	2.1	1
143	Matrix Metalloproteinases as Drug Targets in Acute Pulmonary Embolism. <i>Current Drug Targets</i> , 2013, 14, 344-352.	2.1	0
144	Elevated Plasma Hemoglobin Levels Increase Nitric Oxide Consumption in Experimental and Clinical Acute Pulmonary Thromboembolism*. <i>Critical Care Medicine</i> , 2013, 41, e118-e124.	0.9	17

#	ARTICLE	IF	CITATIONS
145	Matrix Metalloproteinases as Drug Targets in Preeclampsia. <i>Current Drug Targets</i> , 2013, 14, 325-334.	2.1	56
146	Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations. <i>Current Drug Targets</i> , 2013, 14, 335-343.	2.1	49
147	Matrix Metalloproteinases as Drug Targets in Acute Pulmonary Embolism. <i>Current Drug Targets</i> , 2013, 14, 344-352.	2.1	11
148	Endothelial Nitric Oxide Synthase Polymorphism rs3918226 Associated With Hypertension Does Not Affect Plasma Nitrite Levels in Healthy Subjects. <i>Hypertension</i> , 2012, 59, e52; author reply e53.	2.7	16
149	Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans. <i>Vascular Medicine</i> , 2012, 17, 73-78.	1.5	11
150	Functional Polymorphism Located in <i>MMP-9</i> Gene Promoter Is Strongly Associated with Obesity. <i>DNA and Cell Biology</i> , 2012, 31, 1054-1057.	1.9	17
151	Blood transfusions increase circulating plasma free hemoglobin levels and plasma nitric oxide consumption: a prospective observational pilot study. <i>Critical Care</i> , 2012, 16, R95.	5.8	69
152	Comprehensive Evaluation of the Effects of Enalapril on Matrix Metalloproteinases Levels in Hypertension. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 511-519.	2.6	17
153	Interaction among nitric oxide (NO)-related genes in migraine susceptibility. <i>Molecular and Cellular Biochemistry</i> , 2012, 370, 183-189.	3.1	34
154	Functional matrix metalloproteinase (MMP)-9 genetic variants modify the effects of hemodialysis on circulating MMP-9 levels. <i>Clinica Chimica Acta</i> , 2012, 414, 46-51.	1.1	12
155	Evaluation of plasmatic MMP-8, MMP-9, TIMP-1 and MPO levels in obese and lean women. <i>Clinical Biochemistry</i> , 2012, 45, 412-415.	1.9	52
156	Genetic Variants in Matrix Metalloproteinase-9 Gene Modify Metalloproteinase-9 Levels in Black Subjects. <i>DNA and Cell Biology</i> , 2012, 31, 504-510.	1.9	19
157	Doxycycline ameliorates 2K-1C hypertension-induced vascular dysfunction in rats by attenuating oxidative stress and improving nitric oxide bioavailability. <i>Nitric Oxide - Biology and Chemistry</i> , 2012, 26, 162-168.	2.7	60
158	Time course involvement of matrix metalloproteinases in the vascular alterations of renovascular hypertension. <i>Matrix Biology</i> , 2012, 31, 261-270.	3.6	62
159	Circulating matrix metalloproteinases and their inhibitors in hypertension. <i>Clinica Chimica Acta</i> , 2012, 413, 656-662.	1.1	71
160	Increase in gastric pH reduces hypotensive effect of oral sodium nitrite in rats. <i>Free Radical Biology and Medicine</i> , 2012, 53, 701-709.	2.9	71
161	Epistasis among eNOS, MMP-9 and VEGF maternal genotypes in hypertensive disorders of pregnancy. <i>Hypertension Research</i> , 2012, 35, 917-921.	2.7	31
162	Functional MMP-9 polymorphisms modulate plasma MMP-9 levels in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2012, 249, 56-59.	2.3	21

#	ARTICLE	IF	CITATIONS
163	Specific matrix metalloproteinase 9 (MMP-9) haplotype affect the circulating MMP-9 levels in women with migraine. <i>Journal of Neuroimmunology</i> , 2012, 252, 89-94.	2.3	19
164	Matrix Metalloproteinase (MMP)-2 Genetic Variants Modify the Circulating MMP-2 Levels in End-Stage Kidney Disease. <i>American Journal of Nephrology</i> , 2012, 35, 209-215.	3.1	23
165	<i>e</i> NOS Tag SNP Haplotypes in Hypertensive Disorders of Pregnancy. <i>DNA and Cell Biology</i> , 2012, 31, 1665-1670.	1.9	21
166	Vitamin D receptor polymorphisms in hypertensive disorders of pregnancy. <i>Molecular Biology Reports</i> , 2012, 39, 10903-10906.	2.3	24
167	Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during acute pulmonary thromboembolism. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2012, 385, 685-696.	3.0	20
168	Inducible nitric oxide synthase haplotype associated with migraine and aura. <i>Molecular and Cellular Biochemistry</i> , 2012, 364, 303-308.	3.1	35
169	Antihypertensive and antioxidant effects of a single daily dose of sodium nitrite in a model of renovascular hypertension. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2012, 385, 509-517.	3.0	40
170	Imbalanced Matrix Metalloproteinases in Cardiovascular Complications of End-Stage Kidney Disease: A Potential Pharmacological Target. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 110, 409-415.	2.5	16
171	Oral Contraceptive Containing Chlormadinone Acetate and Ethinylestradiol Reduces Plasma Concentrations of Matrix Metalloproteinase-2 in Women with Polycystic Ovary Syndrome. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 111, 211-216.	2.5	4
172	Effects of Matrix Metalloproteinase (MMP)-2 Polymorphisms on Responsiveness to Antihypertensive Therapy of Women with Hypertensive Disorders of Pregnancy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 111, 262-267.	2.5	21
173	Intron 4 polymorphism of the endothelial nitric oxide synthase (eNOS) gene is associated with decreased NO production in a mercury-exposed population. <i>Science of the Total Environment</i> , 2012, 414, 708-712.	8.0	18
174	Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy. <i>Experimental and Molecular Pathology</i> , 2012, 92, 217-221.	2.1	57
175	Losartan exerts no protective effects against acute pulmonary embolism-induced hemodynamic changes. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2012, 385, 211-217.	3.0	5
176	Endogenous nitric oxide formation correlates negatively with circulating matrix metalloproteinase (MMP)-2 and MMP-9 levels in black subjects. <i>Molecular and Cellular Biochemistry</i> , 2012, 360, 393-399.	3.1	13
177	Matrix metalloproteinase (MMP)-9 and VEGF gene interaction models and MMP-9 plasma levels in preeclampsia and gestational hypertension. <i>FASEB Journal</i> , 2012, 26, 848.3.	0.5	1
178	Low nitric oxide bioavailability predicts better responses to sildenafil in patients with erectile dysfunction. <i>FASEB Journal</i> , 2012, 26, 848.1.	0.5	0
179	Vascular Endothelial Growth Factor Haplotypes Associated with Childhood Obesity. <i>DNA and Cell Biology</i> , 2011, 30, 709-714.	1.9	13
180	Endothelial Nitric Oxide Synthase Haplotypes Associated with Aura in Patients with Migraine. <i>DNA and Cell Biology</i> , 2011, 30, 363-369.	1.9	37

#	ARTICLE	IF	CITATIONS
181	Matrix metalloproteinases: Targets for doxycycline to prevent the vascular alterations of hypertension. <i>Pharmacological Research</i> , 2011, 64, 567-572.	7.1	80
182	Chronic ethanol consumption induces histopathological changes and increases nitric oxide generation in the rat liver. <i>Tissue and Cell</i> , 2011, 43, 384-391.	2.2	16
183	Ethanol consumption increases the expression of endothelial nitric oxide synthase, inducible nitric oxide synthase and metalloproteinases in the rat kidney. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 64, 68-76.	2.4	23
184	Implicações farmacogenéticas de polimorfismos da eNOS para drogas de ação cardiovascular. <i>Arquivos Brasileiros De Cardiologia</i> , 2011, 96, e27-e34.	0.8	18
185	Metalloproteinase inhibition protects against cardiomyocyte injury during experimental acute pulmonary thromboembolism*. <i>Critical Care Medicine</i> , 2011, 39, 349-356.	0.9	47
186	Tamoxifen and Its Metabolites Cause Acute Vasorelaxation of Aortic Rings by Inducing Vasodilator Prostanoid Synthesis. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 58, 647-653.	1.9	5
187	Doxycycline Dose-dependently Inhibits MMP-2-mediated Vascular Changes in 2K1C Hypertension. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 108, 318-325.	2.5	48
188	Consistent Alterations of Circulating Matrix Metalloproteinases Levels in Untreated Hypertensives and in Spontaneously Hypertensive Rats: A Relevant Pharmacological Target. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 109, 130-137.	2.5	47
189	Lead contents in the surface enamel of primary and permanent teeth, whole blood, serum, and saliva of 6- to 8-year-old children. <i>Science of the Total Environment</i> , 2011, 409, 1799-1805.	8.0	25
190	A common matrix metalloproteinase (MMP)-2 polymorphism affects plasma MMP-2 levels in subjects environmentally exposed to mercury. <i>Science of the Total Environment</i> , 2011, 409, 4242-4246.	8.0	23
191	Sildenafil improves the beneficial hemodynamic effects exerted by atorvastatin during acute pulmonary thromboembolism. <i>European Journal of Pharmacology</i> , 2011, 670, 554-560.	3.5	25
192	Chronic ethanol consumption reduces adrenomedullin-induced relaxation in the isolated rat aorta. <i>Alcohol</i> , 2011, 45, 805-814.	1.7	12
193	Sodium nitrite downregulates vascular NADPH oxidase and exerts antihypertensive effects in hypertension. <i>Free Radical Biology and Medicine</i> , 2011, 51, 144-152.	2.9	123
194	Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome. <i>Molecular and Cellular Biochemistry</i> , 2011, 353, 251-257.	3.1	37
195	Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2011, 383, 35-44.	3.0	29
196	Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2011, 383, 547-554.	3.0	62
197	Antihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markers. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 365-370.	1.9	20
198	Alterations in cyclic GMP levels in preeclampsia may reflect increased B-type natriuretic peptide levels and not impaired nitric oxide activity. <i>Clinical Biochemistry</i> , 2011, 44, 1012-1014.	1.9	16

#	ARTICLE	IF	CITATIONS
199	Endothelial Nitric Oxide Genotypes and Haplotypes Are Not Associated with End-Stage Renal Disease. <i>DNA and Cell Biology</i> , 2011, 30, 55-59.	1.9	9
200	Effect of enalapril on circulating NO and oxidative stress markers in hypertensive patients. <i>FASEB Journal</i> , 2011, 25, lb370.	0.5	0
201	Environmental Exposure to Methylmercury is Associated with a Decrease in Nitric Oxide Production. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010, 106, 411-415.	2.5	20
202	Quercetin restores plasma nitrite and nitroso species levels in renovascular hypertension. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2010, 382, 293-301.	3.0	44
203	Whole blood, serum, and saliva lead concentrations in 6- to 8-year-old children. <i>Science of the Total Environment</i> , 2010, 408, 1551-1556.	8.0	36
204	A functional matrix metalloproteinase (MMP)-9 polymorphism modifies plasma MMP-9 levels in subjects environmentally exposed to mercury. <i>Science of the Total Environment</i> , 2010, 408, 4085-4092.	8.0	16
205	Vitamin D receptor haplotypes affect lead levels during pregnancy. <i>Science of the Total Environment</i> , 2010, 408, 4955-4960.	8.0	12
206	Evidence for the involvement of matrix metalloproteinases in the cardiovascular effects produced by nicotine. <i>European Journal of Pharmacology</i> , 2010, 627, 216-222.	3.5	28
207	Increased circulating cell-free hemoglobin levels reduce nitric oxide bioavailability in preeclampsia. <i>Free Radical Biology and Medicine</i> , 2010, 49, 493-500.	2.9	45
208	Fluoride increases lead concentrations in whole blood and in calcified tissues from lead-exposed rats. <i>Toxicology</i> , 2010, 271, 21-26.	4.2	29
209	Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. <i>British Journal of Pharmacology</i> , 2010, 160, 77-87.	5.4	86
210	Gingival crevicular fluid levels of MMP-8, MMP-9, TIMP-2, and MPO decrease after periodontal therapy. <i>Journal of Clinical Periodontology</i> , 2010, 37, 180-190.	4.9	119
211	A Pharmacogenetics-based Approach to Reduce Cardiovascular Mortality with the Prophylactic Use of Statins. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010, 106, 357-361.	2.5	35
212	Chronic Treatment with Quercetin does not Inhibit Angiotensin-Converting Enzyme <i>In Vivo</i> or <i>In Vitro</i> . <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010, 107, 825-829.	2.5	10
213	The Relationship between Blood and Serum Lead Levels in Peripartum Women and their Respective Umbilical Cords. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010, 107, 971-975.	2.5	26
214	Interethnic Differences in the Distribution of Matrix Metalloproteinases Genetic Polymorphisms Are Consistent with Interethnic Differences in Disease Prevalence. <i>DNA and Cell Biology</i> , 2010, 29, 649-655.	1.9	29
215	Effects of eNOS polymorphisms on nitric oxide formation in healthy pregnancy and in pre-eclampsia. <i>Molecular Human Reproduction</i> , 2010, 16, 506-510.	2.8	57
216	Endothelial Nitric Oxide Synthase Haplotypes Associated with Hypertension Do Not Predispose to Cardiac Hypertrophy. <i>DNA and Cell Biology</i> , 2010, 29, 171-176.	1.9	23

#	ARTICLE	IF	CITATIONS
217	Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. <i>Matrix Biology</i> , 2010, 29, 194-201.	3.6	100
218	Matrix Metalloproteinase Inhibition Improves Cardiac Dysfunction and Remodeling in 2-Kidney, 1-Clip Hypertension. <i>Journal of Cardiac Failure</i> , 2010, 16, 599-608.	1.7	67
219	eNOS Gene Polymorphisms May Modify the Effects Produced by Cardiovascular Drugs on Myocardial eNOS Expression and Activity. <i>Journal of Cardiac Failure</i> , 2010, 16, 618.	1.7	0
220	Matrix metalloproteinase (MMP)-9 genotypes and haplotypes in preeclampsia and gestational hypertension. <i>Clinica Chimica Acta</i> , 2010, 411, 874-877.	1.1	42
221	Vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (NOS3) polymorphisms are associated with high relapse risk in childhood acute lymphoblastic leukemia (ALL). <i>Clinica Chimica Acta</i> , 2010, 411, 1335-1340.	1.1	19
222	Interethnic differences in ADMA concentrations and negative association with nitric oxide formation in preeclampsia. <i>Clinica Chimica Acta</i> , 2010, 411, 1457-1460.	1.1	35
223	Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients. <i>Clinica Chimica Acta</i> , 2010, 411, 1940-1944.	1.1	30
224	Hemodynamic effects of inducible nitric oxide synthase inhibition combined with sildenafil during acute pulmonary embolism. <i>Nitric Oxide - Biology and Chemistry</i> , 2010, 23, 284-288.	2.7	30
225	Increases in circulating matrix metalloproteinase-9 levels following fibrinolysis for acute pulmonary embolism. <i>Thrombosis Research</i> , 2010, 125, 549-553.	1.7	11
226	Should we measure serum or plasma lead concentrations?. <i>Journal of Trace Elements in Medicine and Biology</i> , 2010, 24, 147-151.	3.0	16
227	Vascular Endothelial Growth Factor Genetic Polymorphisms and Haplotypes in Women with Migraine. <i>DNA and Cell Biology</i> , 2010, 29, 357-362.	1.9	29
228	Interethnic Differences in the Distribution of Clinically Relevant Vascular Endothelial Growth Factor Genetic Polymorphisms. <i>DNA and Cell Biology</i> , 2009, 28, 567-572.	1.9	24
229	Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 888-91.	2.3	31
230	Matrix metalloproteinase-9 genotypes and haplotypes are associated with multiple sclerosis and with the degree of disability of the disease. <i>Journal of Neuroimmunology</i> , 2009, 214, 128-131.	2.3	27
231	Lead in saliva from lead-exposed and unexposed children. <i>Science of the Total Environment</i> , 2009, 407, 1547-1550.	8.0	43
232	Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. <i>Free Radical Biology and Medicine</i> , 2009, 46, 1298-1307.	2.9	143
233	Isoflavone genistein inhibits the angiotensin-converting enzyme and alters the vascular responses to angiotensin I and bradykinin. <i>European Journal of Pharmacology</i> , 2009, 607, 173-177.	3.5	35
234	Evidence of early involvement of matrix metalloproteinase-2 in lead-induced hypertension. <i>Archives of Toxicology</i> , 2009, 83, 439-449.	4.2	22

#	ARTICLE	IF	CITATIONS
235	Assessment of Vascular Effects of Tamoxifen and Its Metabolites on the Rat Perfused Hindquarter Vascular Bed. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2009, 104, 400-407.	2.5	19
236	Mercury Exposure Increases Circulating Net Matrix Metalloproteinase (MMP)-2 and MMP-9 Activities. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2009, 105, 281-288.	2.5	18
237	Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. <i>Clinical Biochemistry</i> , 2009, 42, 984-990.	1.9	56
238	Circulating Interleukin-6 and High-Sensitivity C-Reactive Protein Decrease After Periodontal Therapy in Otherwise Healthy Subjects. <i>Journal of Periodontology</i> , 2009, 80, 594-602.	3.4	118
239	Aldosterone synthase gene polymorphism is not associated with gestational hypertension or preeclampsia. <i>Clinica Chimica Acta</i> , 2009, 400, 139-141.	1.1	11
240	Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. <i>Clinica Chimica Acta</i> , 2009, 403, 173-177.	1.1	81
241	Circulating cell-free DNA levels in plasma increase with severity in experimental acute pulmonary thromboembolism. <i>Clinica Chimica Acta</i> , 2009, 409, 112-116.	1.1	29
242	Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy. <i>Clinica Chimica Acta</i> , 2009, 409, 117-122.	1.1	75
243	Nitrite or sildenafil, but not BAY 41-2272, blunt acute pulmonary embolism-induced increases in circulating matrix metalloproteinase-9 and oxidative stress. <i>Thrombosis Research</i> , 2009, 124, 349-355.	1.7	32
244	Endothelial Nitric Oxide Synthase Polymorphisms and Haplotypes in Amerindians. <i>DNA and Cell Biology</i> , 2009, 28, 329-334.	1.9	35
245	Haplotypes of vitamin D receptor modulate the circulating levels of lead in exposed subjects. <i>Archives of Toxicology</i> , 2008, 82, 29-36.	4.2	45
246	Differences in both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices. <i>Analytical Biochemistry</i> , 2008, 374, 56-63.	2.4	27
247	Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. <i>Clinical Biochemistry</i> , 2008, 41, 875-880.	1.9	95
248	Assessment of How Pregnancy Modifies Plasma Lead and Plasma/Whole Blood Lead Ratio in ALAD 1-1 Genotype Women. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 102, 347-351.	2.5	9
249	Sildenafil Improves the Beneficial Haemodynamic Effects of Intravenous Nitrite Infusion during Acute Pulmonary Embolism. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 103, 374-379.	2.5	28
250	Dose-dependent beneficial hemodynamic effects of BAY 41-2272 in a canine model of acute pulmonary thromboembolism. <i>European Journal of Pharmacology</i> , 2008, 581, 132-137.	3.5	30
251	Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. <i>European Journal of Pharmacology</i> , 2008, 591, 224-230.	3.5	47
252	Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats. <i>European Journal of Pharmacology</i> , 2008, 599, 110-116.	3.5	30

#	ARTICLE	IF	CITATIONS
253	<i>e</i> NOS haplotypes associated with gestational hypertension or preeclampsia. <i>Pharmacogenomics</i> , 2008, 9, 1467-1473.	1.3	82
254	Enhanced concentrations of relevant markers of nitric oxide formation after exercise training in patients with metabolic syndrome. <i>Nitric Oxide - Biology and Chemistry</i> , 2008, 19, 345-350.	2.7	61
255	A plateau detected in lead accumulation in subsurface deciduous enamel from individuals exposed to lead may be useful to identify children and regions exposed to higher levels of lead. <i>Environmental Research</i> , 2008, 107, 264-270.	7.5	23
256	Severity dependent increases in circulating cardiac troponin I and MMP-9 concentrations after experimental acute pulmonary thromboembolism. <i>Clinica Chimica Acta</i> , 2008, 388, 184-188.	1.1	23
257	Inverse relationship between markers of nitric oxide formation and plasma matrix metalloproteinase-9 levels in healthy volunteers. <i>Clinica Chimica Acta</i> , 2008, 394, 72-76.	1.1	35
258	Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. <i>Atherosclerosis</i> , 2008, 198, 320-331.	0.8	170
259	Reply letter to: Genetic modulation of antiinflammatory effects of atorvastatin: Probably a multi-gene condition. <i>Atherosclerosis</i> , 2008, 197, 467-468.	0.8	1
260	Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 57-63.	2.3	41
261	Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension. <i>Molecular Human Reproduction</i> , 2008, 15, 115-120.	2.8	54
262	Nitric Oxide Formation Is Inversely Related to Serum Levels of Antiangiogenic Factors Soluble Fms-Like Tyrosine Kinase-1 and Soluble Endogline in Preeclampsia. <i>Hypertension</i> , 2008, 52, 402-407.	2.7	161
263	Silicate Increases the Release of MMP-9 Forms in Peripheral Blood: Why Gelatin Zymography Differs Significantly in Citrate Plasma and Serum Obtained with or without Clot Activators. <i>Clinical Chemistry</i> , 2007, 53, 1981-1982.	3.2	17
264	Endothelial Nitric Oxide Synthase Polymorphisms and Susceptibility to Hypertension: Genotype Versus Haplotype Analysis. <i>Hypertension</i> , 2007, 49, E1; author reply E2.	2.7	12
265	Protective effects of atorvastatin in rat models of acute pulmonary embolism: Involvement of matrix metalloproteinase-9*. <i>Critical Care Medicine</i> , 2007, 35, 239-245.	0.9	94
266	Haplotype analysis can provide improved clinical information than single genotype analysis. <i>Thrombosis Research</i> , 2007, 120, 779.	1.7	8
267	Influence of <i>e</i> NOS haplotypes on the plasma nitric oxide products concentrations in hypertensive and type 2 diabetes mellitus patients. <i>Nitric Oxide - Biology and Chemistry</i> , 2007, 16, 348-355.	2.7	77
268	An interethnic comparison of the distribution of vitamin D receptor genotypes and haplotypes. <i>Clinica Chimica Acta</i> , 2007, 384, 155-159.	1.1	24
269	A role for matrix metalloproteinase-9 in the hemodynamic changes following acute pulmonary embolism. <i>International Journal of Cardiology</i> , 2007, 114, 22-27.	1.7	39
270	Anti-inflammatory effects of atorvastatin: Modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. <i>Atherosclerosis</i> , 2007, 193, 438-444.	0.8	71

#	ARTICLE	IF	CITATIONS
271	Cardiovascular Mortality in High-Risk Patients and T-786C Polymorphism in Promoter Region of the Endothelial Nitric Oxide Synthase Gene. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1225-1226.	2.8	0
272	Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes. <i>Free Radical Biology and Medicine</i> , 2007, 43, 987-992.	2.9	97
273	Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. <i>Clinical Biochemistry</i> , 2007, 40, 119-123.	1.9	104
274	Susceptible and protective eNOS haplotypes in hypertensive black and white subjects. <i>Atherosclerosis</i> , 2006, 186, 428-432.	0.8	91
275	Endothelial nitric oxide synthase haplotypes affect the susceptibility to hypertension in patients with type 2 diabetes mellitus. <i>Atherosclerosis</i> , 2006, 189, 241-246.	0.8	75
276	A polymorphism in the delta-aminolevulinic acid dehydratase gene modifies plasma/whole blood lead ratio. <i>Toxicology Letters</i> , 2006, 164, S158.	0.8	1
277	Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in congestive heart failure. <i>American Heart Journal</i> , 2006, 152, e9.	2.7	65
278	Contrasting effects of age on the plasma/whole blood lead ratio in men and women with a history of lead exposure. <i>Environmental Research</i> , 2006, 102, 90-95.	7.5	23
279	Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. <i>Clinica Chimica Acta</i> , 2006, 365, 183-187.	1.1	42
280	Ethnicity affects the distribution of δ -aminolevulinic acid dehydratase (ALAD) genetic variants. <i>Clinica Chimica Acta</i> , 2006, 367, 192-195.	1.1	22
281	Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases. <i>Clinica Chimica Acta</i> , 2006, 373, 180-181.	1.1	13
282	Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 617-618.	1.4	0
283	Hemodynamic effects of sildenafil interaction with a nitric oxide donor compound in a dog model of acute pulmonary embolism. <i>Life Sciences</i> , 2006, 79, 469-474.	4.3	40
284	eNOS genotype-dependent correlation between whole blood lead and plasma nitric oxide products concentrations. <i>Nitric Oxide - Biology and Chemistry</i> , 2006, 14, 58-64.	2.7	30
285	Endothelial nitric oxide synthase genotype and haplotype are not associated with diabetic retinopathy in diabetes type 2 patients. <i>Nitric Oxide - Biology and Chemistry</i> , 2006, 15, 417-422.	2.7	30
286	l-Arginine and Pulmonary Embolism. <i>Critical Care Medicine</i> , 2006, 34, 934.	0.9	0
287	l-Arginine and Pulmonary Embolism. <i>Critical Care Medicine</i> , 2006, 34, 934-935.	0.9	1
288	Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy. <i>Journal of Hypertension</i> , 2006, 24, 2393-2397.	0.5	52

#	ARTICLE	IF	CITATIONS
289	Matrix Metalloproteinase-9 Activity in Plasma Correlates with Plasma and Whole Blood Lead Concentrations. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 98, 559-564.	2.5	26
290	A polymorphism in the delta-aminolevulinic acid dehydratase gene modifies plasma/whole blood lead ratio. <i>Archives of Toxicology</i> , 2006, 80, 394-398.	4.2	49
291	Clinical evidence for lead-induced inhibition of nitric oxide formation. <i>Archives of Toxicology</i> , 2006, 80, 811-816.	4.2	43
292	eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite. <i>Free Radical Biology and Medicine</i> , 2006, 41, 1044-1049.	2.9	74
293	Low-dose intravenous nitrite improves hemodynamics in a canine model of acute pulmonary thromboembolism. <i>Free Radical Biology and Medicine</i> , 2006, 41, 1764-1770.	2.9	74
294	Sildenafil reduces cardiovascular remodeling associated with hypertensive cardiomyopathy in NOS inhibitor-treated rats. <i>European Journal of Pharmacology</i> , 2006, 542, 141-147.	3.5	38
295	Serum samples should not be used to assess circulating matrix metalloproteinase-9 levels as a prognostic marker of disease. <i>International Journal of Cancer</i> , 2006, 118, 789-789.	5.1	2
296	Lercanidipine Reduces Matrix Metalloproteinase-9 Activity in Patients With Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, 117-122.	1.9	83
297	Letter to the Editor. <i>Multiple Sclerosis Journal</i> , 2006, 12, 120-120.	3.0	3
298	L-arginine Attenuates Acute Pulmonary Embolism-Induced Increases in Lung Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9. <i>Chest</i> , 2005, 128, 3705-3710.	0.8	50
299	Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 565-570.	1.5	91
300	The Effect of Sildenafil on Pulmonary Embolism-Induced Oxidative Stress and Pulmonary Hypertension. <i>Anesthesia and Analgesia</i> , 2005, 101, 115-120.	2.2	77
301	Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. <i>Clinical Biochemistry</i> , 2005, 38, 410-414.	1.9	109
302	Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. <i>Analytical Biochemistry</i> , 2005, 344, 147-149.	2.4	115
303	Hemodynamic effects of combined sildenafil and L-arginine during acute pulmonary embolism-induced pulmonary hypertension. <i>European Journal of Pharmacology</i> , 2005, 524, 126-131.	3.5	49
304	A Critical Review of Biomarkers Used for Monitoring Human Exposure to Lead: Advantages, Limitations, and Future Needs. <i>Environmental Health Perspectives</i> , 2005, 113, 1669-1674.	6.0	587
305	Circulating Matrix Metalloproteinase-9 Levels as a Possible Marker of Aortic Stiffness. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, e127.	2.4	3
306	Hemodynamic Benefits of Matrix Metalloproteinase-9 Inhibition by Doxycycline During Experimental Acute Pulmonary Embolism. <i>Angiology</i> , 2005, 56, 611-617.	1.8	44

#	ARTICLE	IF	CITATIONS
307	Circulating Matrix Metalloproteinase-9 Levels as a Biomarker of Disease. <i>Clinical Cancer Research</i> , 2005, 11, 8887-8888.	7.0	6
308	eNOS genotype is without effect on circulating nitrite/nitrate level in healthy male population. <i>Thrombosis Research</i> , 2005, 115, 375-379.	1.7	50
309	l-Arginine attenuates acute pulmonary embolism-induced oxidative stress and pulmonary hypertension. <i>Nitric Oxide - Biology and Chemistry</i> , 2005, 12, 9-14.	2.7	80
310	Consistent interethnic differences in the distribution of clinically relevant endothelial nitric oxide synthase genetic polymorphisms. <i>Nitric Oxide - Biology and Chemistry</i> , 2005, 12, 177-182.	2.7	140
311	Sildenafil selectively inhibits acute pulmonary embolism-induced pulmonary hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2005, 18, 181-186.	2.6	79
312	Biological activity of nitric oxide in the plasmatic compartment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 11477-11482.	7.1	144
313	Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. <i>European Journal of Pharmacology</i> , 2004, 498, 189-194.	3.5	62
314	Pharmacologic Therapy of Pulmonary Vasoconstriction in Acute Pulmonary Embolism. <i>Anesthesia and Analgesia</i> , 2004, 98, 273.	2.2	0
315	Hypertension Plus Diabetes Mimics the Cardiomyopathy Induced by Nitric Oxide Inhibition in Rats. <i>Chest</i> , 2002, 122, 1412-1420.	0.8	26
316	Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 407-413.	5.7	101
317	Is There a Place for Inhaled Nitric Oxide in the Therapy of Acute Pulmonary Embolism?. <i>Treatments in Respiratory Medicine</i> , 2002, 1, 167-176.	1.2	40
318	Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. <i>Nature Medicine</i> , 2002, 8, 1383-1389.	30.7	1,096
319	Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. <i>Nature Medicine</i> , 2002, 8, 1383-1389.	30.7	496
320	Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 719-725.	5.7	270
321	Acute administration of nicotine impairs the hypotensive responses to bradykinin in rats. <i>European Journal of Pharmacology</i> , 2001, 413, 241-246.	3.5	6
322	Plasma cGMP levels in air embolism-induced acute lung injury. <i>Journal of Critical Care</i> , 2000, 15, 137-141.	2.2	13
323	Endothelin ETA receptor antagonism attenuates the pressor effects of nicotine in rats. <i>European Journal of Pharmacology</i> , 2000, 396, 33-37.	3.5	29
324	Endothelin-1 attenuates bradykinin-induced hypotension in rats. <i>European Journal of Pharmacology</i> , 2000, 397, 367-371.	3.5	7

#	ARTICLE	IF	CITATIONS
325	Transdermal nicotine mimics the smoking-induced endothelial dysfunction. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 167-174.	4.7	45
326	The Hemodynamic Effects of Endothelin Receptor Antagonism During a Venous Air Infusion in Dogs. <i>Anesthesia and Analgesia</i> , 2000, 90, 102-106.	2.2	54
327	Nonselective Endothelin-Receptor Antagonism Attenuates Hemodynamic Changes After Massive Pulmonary Air Embolism in Dogs. <i>Chest</i> , 2000, 118, 175-179.	0.8	78
328	Small-Dose Inhaled Nitric Oxide Attenuates Hemodynamic Changes After Pulmonary Air Embolism in Dogs. <i>Anesthesia and Analgesia</i> , 1999, 88, 1025-1029.	2.2	15
329	Small-Dose Inhaled Nitric Oxide Attenuates Hemodynamic Changes After Pulmonary Air Embolism in Dogs. <i>Anesthesia and Analgesia</i> , 1999, 88, 1025-1029.	2.2	309
330	End-tidal CO ₂ after CO ₂ embolism. <i>Canadian Journal of Anaesthesia</i> , 1998, 45, 913-914.	1.6	0